VLX600
目录号 : GC17093
An anticancer compound
Cas No.:327031-55-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
VLX600 is a compound that is preferentially active against quiescent cancer cells [1].
Abnormal vascularization of solid tumors lead to the development of microenvironments deprived of oxygen and nutrients that harbour slowly growing and metabolically stressed cells, which display enhanced resistance to standard chemotherapeutic agents and repopulate tumours after therapy [1].
VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation and displays tumour growth inhibition in vivo. In HCT116 colon carcinoma multicellular spheroids (MCS), VLX600 resulted in the appearance of central necrotic areas, induced active caspase-3 and led to a strong decrease in clonogenicity of dispersed cells. VLX600 also induced the expression of genes associated with hypoxia, glycolysis and p53 signaling. In HCT116 cells, VLX600 induces an autophagic response [1].
In NMRI nu/nu mice mice, VLX600 was rapidly distributed and finally eliminated with a half-life of 4-5 h. In mice bearing HCT116 and HT29 colon cancer xenografts, VLX600 exhibited antitumour activity and induced the formation of autolysosomes [1].
Reference:
[1].Zhang X, Frykns M, Hernlund E, et al. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun. 2014;5:3295.
| Cas No. | 327031-55-0 | SDF | |
| 化学名 | 1-(2-pyridinyl)-ethanone, 2-(6-methyl-5H-1,2,4-triazino[5,6-b]indol-3-yl)hydrazone | ||
| Canonical SMILES | C/C(C1=NC=CC=C1)=N/NC2=NC3=C(C(C=CC=C4C)=C4N3)N=N2 | ||
| 分子式 | C17H15N7 | 分子量 | 317.4 |
| 溶解度 | ≤1mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C,unstable in solution, ready to use. |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1506 mL | 15.753 mL | 31.506 mL |
| 5 mM | 0.6301 mL | 3.1506 mL | 6.3012 mL |
| 10 mM | 0.3151 mL | 1.5753 mL | 3.1506 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。